Dataset Information

Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA.

ABSTRACT:

Background

The purpose of this study was to describe comorbidities, healthcare costs, and resource utilization among patients with chronic non-infectious uveitis initiating corticosteroid, immunosuppressants, or biologics.In this retrospective cohort study, patients with a non-infectious uveitis diagnosis and continuous insurance coverage during a 6-month baseline were selected from a privately insured claims database with 80.7 million enrollees. Index dates were defined as the first prescription/administration of a corticosteroid, immunosuppressant, or biologic between 2003 and 2009. Comorbidities, healthcare costs, and utilization were analyzed in a per-member-per-month (PMPM) framework to account for varying between-patient treatment periods, defined as continuous medication use within the same class. Wilcoxon rank-sum and chi-square tests were used for comparisons of costs and categorical outcomes.

Results

Patients on corticosteroids (N?=?4,568), immunosuppressants (N?=?5,466), and biologics (N?=?1,694) formed the study population. Baseline PMPM inpatient admission rates were 0.029 for patients on corticosteroids, 0.044 for patients on immunosuppressants, and 0.045 for patients on biologics (p?ConclusionsThere is significant economic burden associated with existing treatments of uveitis. Corticosteroids may be overused as a treatment for uveitis.

SUBMITTER: Chu DS

PROVIDER: S-EPMC3830557 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA.

Chu David S DS Johnson Scott J SJ Mallya Usha G UG Davis Matthew R MR Sorg Rachael A RA Duh Mei Sheng MS

Journal of ophthalmic inflammation and infection 20131106 1

<h4>Background</h4>The purpose of this study was to describe comorbidities, healthcare costs, and resource utilization among patients with chronic non-infectious uveitis initiating corticosteroid, immunosuppressants, or biologics.In this retrospective cohort study, patients with a non-infectious uveitis diagnosis and continuous insurance coverage during a 6-month baseline were selected from a privately insured claims database with 80.7 million enrollees. Index dates were defined as the first pre ...[more]

PMID: 24195808

Similar Datasets

Project description:OBJECTIVES:To measure 18-month healthcare cost difference attributable to hearing loss (HL) in older adults. DESIGN:Matched cohort. SETTING:Retrospective analysis of administrative healthcare bills of insured older Americans. PARTICIPANTS:Older U.S. adults with health insurance in 3 cohorts matched based on HL diagnosis using propensity score methods (N=904,750). MEASUREMENTS:Comparison groups were defined as those with and without HL diagnosis using International Classification of Diseases, Ninth Revision, diagnosis codes from billing records. Outcomes measured include 18-month total healthcare payments and healthcare payments broken down according to payment type (inpatient, outpatient, prescription, hearing services). Three comparison cohorts were examined for these outcomes: individuals covered by Medicare plus supplemental private insurance (Cohort 1, n=782,216), those covered only under Medicare (Cohort 2, n=105,296), and those within the Medicare sample that were dually eligible for Medicare and Medicaid coverage (Subcohort 3, n=17,238). The quality of the propensity score match was examined using standardized differences in means or proportions between all matched covariates, and cost outcomes were analyzed using multiple generalized linear regression models. RESULTS:Fully adjusted models showed significantly higher 18-month healthcare payments for individuals with a diagnosis of HL without indication of use of hearing services than in those without a HL diagnosis in the 3 samples (payment differences: $3,587 Cohort 1, $3,779 Cohort 2, $4,657 Subcohort 3; all p<.001). Payment differences were also found between individuals with HL and indications of hearing services and those without HL. CONCLUSION:We observed more than 20% higher total healthcare payments over 18 months for a group of insured individuals with HL regardless of insurance type or hearing services use, indicating that negative health-related effects of HL may increase healthcare use unrelated to HL. Thus, clinical care to ameliorate HL may improve overall health.

Dataset Information

Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA.

Background

Results

Publications

Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets